




ZCTIQ

A CANCER DIAGNOSTIC COMPANY

Company Presentation

May 2009





Opportunity Overview

- The core of successful cancer treatment utilizes cancer diagnostic tools – a multimillion \$ market
- Zetiq has developed a cost effective set of proprietary tools to **screen**, monitor and diagnose cancer by generating **color discrimination** between non cancer cells and a wide range of cancer cells
- Zetiq has **positive** clinical data, with a clear clinical and regulatory development plan that will introduce our products to the market in the next two years
- Zetiq has experienced managers in the life science industry. We are guided by excellent board and scientific board highly esteemed U.S and Israeli professionals
- Zetiq is seeking investment and strategic partnering to achieve regulatory approval and marketing of our diagnostic products



Market Dynamics

Cervical cancer


- In women worldwide, cervical cancer is second only to breast cancer in its incidence and mortality
- The available Pap screening test suffers from major drawbacks. Still, this only in-vitro cancer screening test has an over \$1.5 billion market size in the U.S. alone, with around 70 million tests performed annually
- In developing countries where cervical cancer is most prevalent today, current tools do not fulfill the unmet need for effective screening

Bladder Cancer

- Bladder cancer is one of the most commonly occurring cancers
- At least 75% of Bladder patients present disease recurrence, no effective screening technique is available, and market size is estimated to exceeds \$500 million

Product Development Overview

- The CellDetect™ technology enables dual analysis of color discrimination and morphological examination, advancing increased sensitivity and specificity detection of cancer and pre-cancer cells
- Successful Completion of study for detecting cancer in cervical biopsies, and advanced stages of clinical study for detecting cervical abnormalities in cytological smears towards a cervical cancer screening product
- Initiated clinical study for the development of a Bladder monitoring cytology product
- Extensive pre clinical data in tissue culture cells as well as in human tissues
- Broad patent application covering the platform technology and its uses, National phase (NP) filed in many jurisdictions





Value Proposition

- Sensitive and specific cancer detection
- Wide variety of cancer indications
- Multiple diagnosis applications
- Cost effective operational process for both high and low resourced environments
- Effective analysis and detection



Effective Cancer Diagnosis

Zetiq Technologies LTD

Paz Tower 1, 5 Shoham St., Ramat Gan 52521, Israel. Tel: 972-3-753-4100; Fax: 972-3-7515134; www.zetiq.co.il